Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dth.13139 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Granulomatosis With Polyangiitis in a Young Lady: Challenges in Achieving Remission.
Cureus
December 2024
Ophthalmology, Universiti Kebangsaan Malaysia Medical Centre (UKMMC), Kuala Lumpur, MYS.
Granulomatosis with polyangiitis (GPA) is a subtype of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) that commonly requires aggressive immunosuppression to achieve remission. We present a case of a young Malay lady with recurrent episodes of ANCA-positive nodular anterior scleritis who responded poorly to topical and systemic corticosteroids and relapsed while on methotrexate. A year later, she had epistaxis, and a sino-nasal biopsy confirmed granulomatous vasculitis.
View Article and Find Full Text PDFCase report: HSV lymphadenitis in immunocompromised patient with CLL.
Front Oncol
December 2024
Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, United States.
Background: Richter's transformation (RT) in chronic lymphocytic leukemia (CLL) is associated with poor prognosis and requires prompt modifications in patient care. CLL patients are susceptible to severe infections due to immune dysregulation induced by their malignancy and immunosuppressive therapies.
Case Presentation: We present a case of a 63-year-old man with CLL who previously achieved remission and presented with a right inguinal mass.
Phenotypic patterns and response to immunotherapy in a group of Very Late Onset Myasthenia Gravis: a single center study.
Neurol Sci
December 2024
1st Neurology Department, Aeginition Hospital, National and Kapodistrian University of Athens, 74 Vas. Sophias Ave., 11528, Athens, Greece.
Background/aims: The goal of this study was to assess the clinical profile of myasthenia gravis (MG) in patients diagnosed above 65-years of age (VLOMG) and identify clinical/serological parameters associated with their MG status and prognosis.
Methods: This was a retrospective assessment of consecutive patients with VLOMG (n = 70) Demographics, clinical characteristics, medical comorbidities, the Myasthenia Gravis Foundation of America (MGFA) severity scale scores, and MGFA Post-Intervention Status (MGFA-PIS) were collected.
Results: The research population was diagnosed with MG at an average age of 73.
Approaches to management of HIT in complex scenarios, including cardiac surgery.
Hematology Am Soc Hematol Educ Program
December 2024
Division of Hematology, Department of Medicine, Duke University Medical Center, Durham, NC.
Although heparin-induced thrombocytopenia (HIT) presents management challenges for any population, it adds complexity to the management of certain patient populations, including those undergoing cardiac surgery and those with refractory HIT and/or acute bleeding. For each of these scenarios, we review alternative management strategies when standard therapies-heparin cessation and the initiation of a nonheparin anticoagulant-are either insufficient or not practicable. In patients with HIT undergoing cardiac surgery, we review the clinical experience for heparin reexposure using therapeutic plasma exchange (TPE) or antiplatelet therapy.
View Article and Find Full Text PDFRetrospective Analysis of Rituximab Therapy for Myasthenia Gravis: A Case Series.
Cureus
November 2024
Laboratory Department, King Fahad Specialist Hospital, Tabouk, SAU.
Myasthenia gravis (MG) is a neuromuscular junction disorder that involves several dysfunctions that eventually lead to muscle fatigue and weakness. Although immunotherapeutics are considered an effective treatment option for MG, treatment-refractory cases are documented. In this case report, we evaluate the efficacy and safety of rituximab in treating three cases of myasthenia gravis admitted to the neurology department of a tertiary hospital.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!